MRNS Marinus Pharmaceuticals Inc.

1.26
+0.16  (+15%)
Previous Close 1.1
Open 1.15
Price To Book 2
Market Cap 67,875,314
Shares 53,869,297
Volume 2,265,063
Short Ratio
Av. Daily Volume 1,226,652
Stock charts supplied by TradingView

NewsSee all news

  1. Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RADNOR, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  2. Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

     Positive Phase 2 IV ganaxolone data in RSE Strong enrollment continues in pivotal CDD study RADNOR, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company

  3. Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer

    RADNOR, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy,

  4. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  5. Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

    All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October Conference call and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated mid-2020.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 negative data released July 23, 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 3 top-line data due 3Q 2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Phase 3 top-line data due 2021.
Ganaxolone (Violet Study)
PCDH19-related epilepsy

Latest News

  1. Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RADNOR, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  2. Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

     Positive Phase 2 IV ganaxolone data in RSE Strong enrollment continues in pivotal CDD study RADNOR, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company

  3. Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer

    RADNOR, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy,

  4. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  5. Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

    All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October Conference call and

  6. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat